Tacit Therapeutics Announces Series A Financing to Advance RNA Trans-Splicing Medicines for Inherited Diseases
Tacit Therapeutics, an RNA trans-splicing company developing programmable RNA repair medicines, today announced the closing of its Series A financing bringing the company’s total capital raised to $19 million.
